| 1. | GALE, J., Pfizer Inc., Inflammation and Immunology Research Unit, Statele Unite ale Americii, BERGER, B., Retina Research Center, Austin, Statele Unite ale Americii, GILBERT, S., Early Clinical Development, Pfizer, Inc, Cambridge, MA, Statele Unite ale Americii, POPA, S., dr., SULTAN, M., Global Product Development, Pfizer, Inc, New York, NY, Statele Unite ale Americii, SCHACHAR, R., Clinical Affairs, Pfizer Essential Health, Pfizer, Inc, San Diego, CA, Statele Unite ale Americii, GIRGENTI, D., Global Product Development, Pfizer, Inc, New York, NY, Statele Unite ale Americii, PERROS-HUGUET, C., Pfizer Inc., Inflammation and Immunology Research Unit, Statele Unite ale Americii A CCR2/5 inhibitor, PF-04634817, is inferior to monthly ranibizumab in the treatment of diabetic macular edema. Investigative Ophthalmology and Visual Science. 2018, nr. 6(59), 2669-2659. ISSN 0146-0404. |
